Search PubMed⌕ Search

Biomedical subjects

J R Bohl

Publications and source records attributed to J R Bohl.

3 recordsLinked to original sources

Immunohistochemical investigation of the brain of aged dogs. I. Detection of neurofibrillary tangles and of 4-hydroxynonenal protein, an oxidative damage product, in senile plaques.

In the aging dog brain lesions develop spontaneously. They share some morphological characteristics with those of Alzheimer 's disease in man. Diffuse and primitive plaques are well known, whereas neuritic plaques rarely develop. Neurofibrillary tangles have not been seen in the canine. The aim of the present investigation was to study major age-related changes of the dog's brain using paraffin sections with respect to cross-immunoreactivity of tau, A beta protein and other immunoreactive components including hydroxynonenal protein, which is a marker for oxidative damage. The occurrence of neurofibrillary tangles and of the protein tau therein was studied in serial brain sections of two dogs with the Gallyas stain and by immunohistochemistry with three different antibodies against tau. Senile plaques were stained with a monoclonal anti-A beta (residues 8-17), polyclonal anti-apolipoprotein E and a monoclonal antibody against 4-hydroxynonenal (HNE). Amyloid deposits and controls were screened by Congo red staining viewed in fluorescent light, followed by polarized light for green birefringence. With the Gallyas stain and one of the antisera against tau, neurofibrillary tangles were revealed in a similar dispersed pattern, whereas the other antitau antisera gave negative results. With the anti-HNE a positive reaction was found in cerebral amyloid deposits and in vascular wall areas where amyloid deposition was confirmed by Congo-red staining, and in perivascular cells and in some neurons. These results indicate that the canine with his tangles and plaques which show oxidative changes, forms a spontaneous modelfor understanding the early changes and their interrelationships in Alzheimer's disease.

Aging↗

The Coventry Award. The effects of shelf life on clinical outcome for gamma sterilized polyethylene tibial components.

Tibial component shelf life was examined as a contributory factor of the in vivo failure of gamma sterilized prosthetic knee replacements. One hundred eighty-eight Synatomic total knee replacements sterilized by gamma irradiation in air were implanted by one surgeon into 147 patients between May 1985 and December 1994. Of these, 135 knees in 105 patients with a mean followup of 5.8 years (range, 2.1-11.3 years) were included in the study. The mean shelf life of the implants was 3.6 years (range, 0.1-10.7 years). Clinical failure for this study was defined as component retrieval resulting from polyethylene degradation. The knee components were divided into three different groups determined by their shelf storage durations of 0 to 4 years (Group 1, 93 components), between 4 and 8 years (Group 2, 21 components), or greater than 8 to 11 years (Group 3, 21 components). Six prostheses were revised because of polyethylene degradation after a mean implantation time of 2.5 years (range, 1.1-3.8 years). The mean shelf life of these six prostheses was 8.4 years (range, 5.8-9.6 years). Five years after implantation, prostheses that had shelf lives of less than 4 years had a 100% survival rate. Those that had shelf lives of 4 to 8 years before implantation had an 88.6% survival rate, and those prostheses that had shelf lives greater than 8 to 11 years had a 79.2% survival rate.

Adult↗

[Cell therapy and its risks].

Parenteral administration of fresh cells, frozen cells (snapfrozen cell suspensions) or lyophilized cells (sicca cells), is known as cellular or cell therapy. While the German Health Office (BGA) provisionally banned the use of dried cell preparations in 1987, injection of fresh cells is still allowed. There have been repeated reports of life-threatening, and even fatal, complications of this type of therapy. Since it involves the administration of heterologous biological material, most of the complications that have been observed have been of the allergic/hyperergic type resembling experimental allergic encephalomyelitis (EAE) and experimental allergic neuritis (EAN). When evaluating the risks of this form of alternative-medical treatment, the well-known risks of injection therapy must also be borne in mind. In the case of cell therapy, too, the hoped for effect must be weighed against the risks of the procedure, and our guiding principle must be: nil nocere.

Cell- and Tissue-Based Therapy↗